Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02463357
Other study ID # 15-0254
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date August 2015
Est. completion date September 2016

Study information

Verified date March 2021
Source University of Colorado, Denver
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute Mountain Sickness (AMS) is a well-documented syndrome that affects 42% of non-acclimatized individuals traveling to altitudes above 10,000 feet. Decreased barometric pressure, which leads to low blood oxygen levels, is the primary casual factor of AMS. Symptoms of AMS are characterized by headache, nausea, vomiting, dizziness, fatigue and difficultly sleeping. Moreover, when people travel to high altitude, cognitive performance and endurance exercise capacity are impaired. Therefore, the goal of this research is to identify effective pharmacological agents that will help reduce the symptoms of AMS and improve physical and cognitive performance at high altitude. The investigators will study the efficacy of the dietary supplement, quercetin, the drugs nifedipine (extended release) and methazolamide taken together, the drug metformin, and the drug nitrite in reducing symptoms of AMS and improving cognitive and exercise performance at high altitudes.


Recruitment information / eligibility

Status Completed
Enrollment 148
Est. completion date September 2016
Est. primary completion date September 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - healthy, - young (18-30 years old) men who can meet APFT requirements for special operation forces (SOF) training as outlined by the US Army (42 push ups, 53 sit-ups, 6 pull-ups, 2 mile run in < 15 min 54 s) Exclusion Criteria: - women; - smokers; - participants with diseases or disorders known to be affected by hypoxia or the drugs used in this study, such as hypotension, anemia, sickle cell trait or disease, and diabetes; - participants with a history of significant head injury, migraines or seizures; - participants taking any medication (over-the-counter or prescription) or herbal supplements; - participants with known flavonoid allergies; - participants with known allergies to metformin; - participants with known hypersensitivity reaction to nifedipine; - participants with known allergies to sulfonamide-based drugs; - participants with inability to be headache-free when consuming the amount of caffeine in two six ounce cups of coffee or less per day; - exposure to high altitude above 1000m in the previous three months; or - participants who have been on an airline flight over six hours (the lowered cabin pressure for an extended period of time approximates exposure to high altitude); - participants who are unable to achieve the minimum physical criteria required for SOF training

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Quercetin

Drug:
Nifedipine extended release

Methazolamide

Metformin

Placebo

Nitrite


Locations

Country Name City State
United States Alma College Alma Michigan

Sponsors (2)

Lead Sponsor Collaborator
University of Colorado, Denver Alma College

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Environmental Symptoms Questionnaire at High Altitude Self-reported assessment of AMS symptoms (headache, lightheaded, dizzy, etc.). The 11-item Environmental Symptoms Questionnaire measures Acute Mountain Sickness symptoms (nausea, weakness, lightheadedness, dizziness, headache, etc.). Possible scores range from 0 to 55 (0-5 per item), with higher scores indicating a better outcome. Baseline and during high altitude exposure (3 days, AM/PM)
Primary Change in Lake Louise AMS Scoring System at High Altitude Self-reported assessment of AMS symptoms (headache, nausea, vomiting, dizziness, fatigue and difficultly sleeping). The Lake Louise AMS Scoring System measures symptoms of altitude sickness. Possible scores range from 0 to 16, with higher scores indicating a worse outcome. Baseline and during high altitude exposure (3 days, AM/PM)
Primary Change in Army Physical Fitness Test (APFT) at High Altitude Timed 2 mile run, push-ups, sit-ups, and pull-ups. The Army Physical Fitness Test (APFT) measures physical fitness. Higher scores indicate a better outcome. A score of 60 is considered minimum "passing" score. The maximum possible score is 300, indicating the highest level of physical fitness. Baseline, 1st day at high altitude
Primary Change in Uphill Hike at High Altitude Timed 3.1 mile uphill run/hike, with weighted back-pack 2nd day at altitude
Primary Change in Defense Automated Neurobehavioral Assessment (DANA) Reaction Time at High Altitude Battery of nine cognitive function tests. The Defense Automated Neurobehavioral Assessment (DANA) measures cognitive function and was used to measure mean reaction time. Possible scores range from 180 to 500 milliseconds, with lower scores indicating a better outcome. Baseline and and 1st day at high altitude
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01182792 - Chronic Mountain Sickness, Systemic Vascular Function N/A
Completed NCT00952302 - Study of the Effects of Iron Levels on the Lungs at High Altitude N/A
Completed NCT04075565 - The Psychophysiological Effect of Simulated and Terrestrial Altitude N/A
Completed NCT01187108 - Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru Phase 1/Phase 2
Completed NCT01587027 - Safety Evaluation of Aminophylline and Methazolamide Phase 1
Not yet recruiting NCT06129825 - Pharmacologic Induction of Tolerance for Hypoxia & Hypothermia